Xian-Liang Tang1, Gregg Rokosh1, Santosh K Sanganalmath1, Yukichi Tokita1, Matthew C L Keith1, Gregg Shirk1, Heather Stowers1, Gregory N Hunt1, Wenjian Wu1, Buddhadeb Dawn1, Roberto Bolli2. 1. From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.). 2. From the Division of Cardiovascular Medicine and Institute of Molecular Cardiology, University of Louisville, KY (X.-L.T., G.R., S.K.S., Y.T., M.C.L.K., G.S., H.S., G.N.H., W.W., R.B.); and Division of Cardiovascular Diseases and the Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City (B.D.). rbolli@louisville.edu.
Abstract
BACKGROUND: Although c-kit(pos) cardiac stem cells (CSCs) preserve left ventricular (LV) function and structure after myocardial infarction, CSC doses have been chosen arbitrarily, and the dose-effect relationship is unknown. METHODS AND RESULTS: Rats underwent a 90-minute coronary occlusion followed by 35 days of reperfusion. Vehicle or CSCs at 5 escalating doses (0.3×10(6), 0.75×10(6), 1.5×10(6), 3.0×10(6), and 6.0×10(6) cells/heart) were given intracoronarily 4 h after reperfusion. The lowest dose (0.3×10(6)) had no effect on LV function and morphology, whereas 0.75, 1.5, and 3.0×10(6) significantly improved regional and global LV function (echocardiography and hemodynamic studies). These 3 doses had similar effects on echocardiographic parameters (infarct wall thickening fraction, LV end-systolic and end-diastolic volumes, LV ejection fraction) and hemodynamic variables (LV end-diastolic pressure, LV dP/dtmax, preload adjusted maximal power, end-systolic elastance, preload recruitable stroke work) and produced similar reductions in apoptosis, scar size, infarct wall thinning, and LV expansion index and similar increases in viable myocardium in the risk region (morphometry). Infusion of 6.0×10(6) CSCs markedly increased postprocedural mortality. Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persistence of donor cells and formation of new myocytes were negligible with all doses. CONCLUSIONS: Surprisingly, in this rat model of acute myocardial infarction, the dose-response relationship for intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75×10(6) is necessary for efficacy; above this threshold, a 4-fold increase in cell number does not produce greater improvement in LV function or structure. Further increases in cell dose are harmful.
BACKGROUND: Although c-kit(pos) cardiac stem cells (CSCs) preserve left ventricular (LV) function and structure after myocardial infarction, CSC doses have been chosen arbitrarily, and the dose-effect relationship is unknown. METHODS AND RESULTS:Rats underwent a 90-minute coronary occlusion followed by 35 days of reperfusion. Vehicle or CSCs at 5 escalating doses (0.3×10(6), 0.75×10(6), 1.5×10(6), 3.0×10(6), and 6.0×10(6) cells/heart) were given intracoronarily 4 h after reperfusion. The lowest dose (0.3×10(6)) had no effect on LV function and morphology, whereas 0.75, 1.5, and 3.0×10(6) significantly improved regional and global LV function (echocardiography and hemodynamic studies). These 3 doses had similar effects on echocardiographic parameters (infarct wall thickening fraction, LV end-systolic and end-diastolic volumes, LV ejection fraction) and hemodynamic variables (LV end-diastolic pressure, LV dP/dtmax, preload adjusted maximal power, end-systolic elastance, preload recruitable stroke work) and produced similar reductions in apoptosis, scar size, infarct wall thinning, and LV expansion index and similar increases in viable myocardium in the risk region (morphometry). Infusion of 6.0×10(6) CSCs markedly increased postprocedural mortality. Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persistence of donor cells and formation of new myocytes were negligible with all doses. CONCLUSIONS: Surprisingly, in this rat model of acute myocardial infarction, the dose-response relationship for intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75×10(6) is necessary for efficacy; above this threshold, a 4-fold increase in cell number does not produce greater improvement in LV function or structure. Further increases in cell dose are harmful.
Authors: Jason M Duran; Catherine A Makarewich; Thomas E Sharp; Timothy Starosta; Fang Zhu; Nicholas E Hoffman; Yumi Chiba; Muniswamy Madesh; Remus M Berretta; Hajime Kubo; Steven R Houser Journal: Circ Res Date: 2013-06-25 Impact factor: 17.367
Authors: Roberto Bolli; Atul R Chugh; Domenico D'Amario; John H Loughran; Marcus F Stoddard; Sohail Ikram; Garth M Beache; Stephen G Wagner; Annarosa Leri; Toru Hosoda; Fumihiro Sanada; Julius B Elmore; Polina Goichberg; Donato Cappetta; Naresh K Solankhi; Ibrahim Fahsah; D Gregg Rokosh; Mark S Slaughter; Jan Kajstura; Piero Anversa Journal: Lancet Date: 2011-11-14 Impact factor: 79.321
Authors: Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare Journal: Circulation Date: 2012-12-05 Impact factor: 29.690
Authors: Sadia Mohsin; Mohsin Khan; Haruhiro Toko; Brandi Bailey; Christopher T Cottage; Kathleen Wallach; Divya Nag; Andrew Lee; Sailay Siddiqi; Feng Lan; Kimberlee M Fischer; Natalie Gude; Pearl Quijada; Daniele Avitabile; Silvia Truffa; Brett Collins; Walter Dembitsky; Joseph C Wu; Mark A Sussman Journal: J Am Coll Cardiol Date: 2012-07-26 Impact factor: 24.094
Authors: Atul R Chugh; Garth M Beache; John H Loughran; Nathan Mewton; Julius B Elmore; Jan Kajstura; Patroklos Pappas; Antone Tatooles; Marcus F Stoddard; Joao A C Lima; Mark S Slaughter; Piero Anversa; Roberto Bolli Journal: Circulation Date: 2012-09-11 Impact factor: 29.690
Authors: Behzad N Oskouei; Guillaume Lamirault; Chacko Joseph; Adriana V Treuer; Stephanie Landa; Jose Da Silva; Konstantinos Hatzistergos; Marc Dauer; Wayne Balkan; Ian McNiece; Joshua M Hare Journal: Stem Cells Transl Med Date: 2012-02-07 Impact factor: 6.940
Authors: Yiru Guo; Marcin Wysoczynski; Yibing Nong; Alex Tomlin; Xiaoping Zhu; Anna M Gumpert; Marjan Nasr; Senthikumar Muthusamy; Hong Li; Michael Book; Abdur Khan; Kyung U Hong; Qianhong Li; Roberto Bolli Journal: Basic Res Cardiol Date: 2017-02-16 Impact factor: 17.165
Authors: Roberto Bolli; Joshua M Hare; Keith L March; Carl J Pepine; James T Willerson; Emerson C Perin; Phillip C Yang; Timothy D Henry; Jay H Traverse; Raul D Mitrani; Aisha Khan; Ivonne Hernandez-Schulman; Doris A Taylor; Darcy L DiFede; João A C Lima; Atul Chugh; John Loughran; Rachel W Vojvodic; Shelly L Sayre; Judy Bettencourt; Michelle Cohen; Lem Moyé; Ray F Ebert; Robert D Simari Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Joseph B Moore; Xian-Liang Tang; John Zhao; Annalara G Fischer; Wen-Jian Wu; Shizuka Uchida; Anna M Gumpert; Heather Stowers; Marcin Wysoczynski; Roberto Bolli Journal: Basic Res Cardiol Date: 2018-11-16 Impact factor: 17.165
Authors: Marcin Wysoczynski; Yiru Guo; Joseph B Moore; Senthilkumar Muthusamy; Qianhong Li; Marjan Nasr; Hong Li; Yibing Nong; Wenjian Wu; Alex A Tomlin; Xiaoping Zhu; Gregory Hunt; Anna M Gumpert; Michael J Book; Abdur Khan; Xian-Liang Tang; Roberto Bolli Journal: J Am Coll Cardiol Date: 2017-04-11 Impact factor: 24.094
Authors: Piotr Musialek; Adam Mazurek; Danuta Jarocha; Lukasz Tekieli; Wojciech Szot; Magdalena Kostkiewicz; R Pawel Banys; Malgorzata Urbanczyk; Andrzej Kadzielski; Mariusz Trystula; Jacek Kijowski; Krzysztof Zmudka; Piotr Podolec; Marcin Majka Journal: Postepy Kardiol Interwencyjnej Date: 2015-06-22 Impact factor: 1.426